Study of TAE added on chemotherapy in patients with metastatic neuroendocrine tumors

Not Applicable

Recruiting

• Conditions: Gastroenteropancreatic neuroendocrine neoplasms

• Registration Number: JPRN-jRCT1061210015
• Lead Sponsor: Kato Hironari

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-21
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

1 Patients who diagnosed with non-functionnal GEP-NEN of which grade was G1 confirmed pathologically
2 Patients with liver metastatic tumors who have no treatment history of TAE and chemotherapy
3 20 age old over
4 Patienst who have been fully informed consent
5 Regardless of gender
6 Less than 1 of performance status
7 Adequate hematologic and end-organ function

Exclusion Criteria

1 Tumor thrombus or thrombus in the main and/or first portal vein
2 Moderate or severe ascites
3 Severe arteriovenous shunt in the liver
4 Allergy for contrast media
5 Less than 30 mL/min of eGFR
6 Allergy for Everolimus, Sirolimus and Sirolimus derivatives
7 Allergy for gelatin
8 Prior treatment with mTOR inhibitor
9 Long treatment with corticosteroids or other immunostimulatory agents
10 Significant cardiovascular, infectious, diabate or plumonary disease
11 The participant has a fasting glycemic level of 1.5 ULN or higher at the start of the screening period
12 Patients who diagnosed as Interstitial pneumonia by CT
13 Being pregnant or possibly pregnant
14 Patients who judged as not suitable for chemotherapy
15 Patients who judged as inappropriate candidate by the chief medical examine

Study & Design

• Study Type: Interventional
• Study Design: Not specified